ArticleMolecular therapy. Methods & clinical development2018
Screening Clinical Cell Products for Replication Competent Retrovirus: The National Gene Vector Biorepository Experience.
Article in Molecular therapy. Methods & clinical development, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 31 citations in OpenAlex.
- Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies.Nature medicine · 2025Article
- The design of retroviral vectors used in the CAR-T products, risk management, and future perspective.MedComm · 2025Article
- In-depth analysis of the safety of CAR-T cell therapy for solid tumors.Frontiers in immunology · 2025Review
- Myelodysplastic Syndrome After Anti-CD19 Chimeric Antigen Receptor T-cell Therapy: A Case Series.Cureus · 2023Article
- Meeting FDA Guidance recommendations for replication-competent virus and insertional oncogenesis testing.Molecular therapy. Methods & clinical development · 2023Review
- Replication competent retrovirus testing (RCR) in the National Gene Vector Biorepository: No evidence of RCR in 1,595 post-treatment peripheral blood samples obtained from 60 clinical trials.Molecular therapy : the journal of the American Society of Gene Therapy · 2023Article
- Genome-wide profiling of retroviral DNA integration and its effect on clinical pre-infusion CAR T-cell products.Journal of translational medicine · 2022Article
- Low rate of subsequent malignant neoplasms after CD19 CAR T-cell therapy.Blood advances · 2022Article
- Lentiviral Vectors for Ocular Gene Therapy.Pharmaceutics · 2022Review
- Article
- Inadvertent Transfer of Murine VL30 Retrotransposons to CAR-T Cells.Advances in cell and gene therapy · 2022Article
- Scalable Manufacturing of CAR T cells for Cancer Immunotherapy.Blood cancer discovery · 2021Review
- Beyond the storm - subacute toxicities and late effects in children receiving CAR T cells.Nature reviews. Clinical oncology · 2021Review
- Review
- Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020Article
- The National Gene Vector Biorepository: Eleven Years of Providing Resources to the Gene Therapy Community.Human gene therapy · 2020Review
- Syncytin 1 dependent horizontal transfer of marker genes from retrovirally transduced cells.Scientific reports · 2019Article
- Clonal expansion of CAR T cells harboring lentivector integration in the CBL gene following anti-CD22 CAR T-cell therapy.Blood advances · 2019Article
- Mechanisms of resistance to CAR T cell therapy.Nature reviews. Clinical oncology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 10 institutions in 1 country.
Funding
Abstract
Replication-competent retrovirus (RCR) is a safety concern for individuals treated with retroviral gene therapy. RCR detection assays are used to detect RCR in manufactured vector, transduced cell products infused into research subjects, and in the research subjects after treatment. In this study, we reviewed 286 control (n = 4) and transduced cell products (n = 282) screened for RCR in the National Gene Vector Biorepository. The transduced cell samples were submitted from 14 clinical trials. All vector products were previously shown to be negative for RCR prior to use in cell transduction. After transduction, all 282 transduced cell products were negative for RCR. In addition, 241 of the clinical trial participants were also screened for RCR by analyzing peripheral blood at least 1 month after infusion, all of which were also negative for evidence of RCR infection. The majority of vector products used in the clinical trials were generated in the PG13 packaging cell line. The findings suggest that screening of the retroviral vector product generated in PG13 cell line may be sufficient and that further screening of transduced cells does not provide added value.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.